admin, Author at Primmune

Rationale for Therapeutic Benefit of PRTX007 in COVID-19 (White Paper)

by admin | Jul 20, 2020 | Uncategorized

To download the white paper, please provide your name and email address. ...

AACR 2020 Poster Download

by admin | Jul 20, 2020 | Uncategorized

Appleman JR, Webber SE. Selection of a novel toll-like receptor 7 (TLR7) agonist PRX034 for immunotherapy of cancer. AACR Virtual Annual Meeting 2020. AACR Virtual Annual Meeting II, June 22-24, 2020. PO.ET05.03 – Experimental and Clinical Therapeutics. Listen...

Primmune Therapeutics Announces the Selection of PRTX007 as Its Clinical Development Candidate for COVID-19 and Oncology Indications

by admin | Mar 31, 2020 | Press Releases

SAN DIEGO, March 31, 2020 – Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications. “PRTX007 is an oral small molecule that specifically...

Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases

by admin | Mar 2, 2020 | Press Releases, Uncategorized

SAN DIEGO, March 2, 2020 – Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate...

SITC 2019 Poster Download

by admin | Nov 8, 2019 | Uncategorized

Appleman JR, Webber SE. Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer. In: 34th Annual Meeting and Pre-conference Programs of the Society for Immunotherapy of Cancer (SITC...